drugset
Drugs / HST-NEETs
last change Jan 2026 re-read 3 minutes ago

HST-NEETs

Cell therapy

Developed for
HIV infectious disease · HIV-associated cancer
Investigated by
Catherine Bollard · Blood and Marrow Transplant Clinical Trials Network · Children's National Research Institute · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Marrow Donor Program

Trials 2

today NCT04975698 · Ph 2 NCT03485963 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03485963 Mar 2019 → Sep 2021 HIV infectious disease Catherine Bollard Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04975698 Oct 2021 → Nov 2025 HIV-associated cancer Catherine Bollard Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HST-NEETs ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975698 ↗
1

NCT03485963 ↗
Modality Cell therapy “ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET)” NCT03485963 ↗
Route Intravenous “administered as a single intravenous (IV) infusion” NCT04975698 ↗